Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making ...

Nurix Therapeutics Showcases Promising Preclinical Data for BTK, BRAF, and Aurora A Kinase Degraders at AACR 2025 Annual Meeting April 25, 2025 — 01:12 pm EDT ...

Holmen and her team first examined what causes melanoma cells to spread to the brain and identified focal adhesion kinase (FAK) as a potential target for new therapies.

Podder V, Ganiyani MA, Ahmad S, et al. Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis. J Clin Oncol. 42, 2024 (suppl 16; ...

Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about one-fifth to one-quarter of patients. Many brain metastases will be ...

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward Dec. 16, 2024 11:36 AM ET Puma Biotechnology, Inc. (PBYI) Stock PBYI 6 Comments Galzus Research ...

ALISCATM-Breast1 study evaluates alisertib in HR-positive, HER2-negative metastatic breast cancer with 150 patients across three dosage groups. Alisertib, an Aurora A kinase inhibitor, is combined ...

Brain metastases, as these secondary tumors are called, most commonly arise from solid tumors like breast, lung, and colon cancer and are often associated with a poor prognosis.

An estimated 10% to 40% of patients with solid tumors develop brain metastases.Incidence — which is highest among those with primary melanoma or lung, breast, colon or kidney cancers — has ...

A new editorial paper titled "Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?" has been published in Oncotarget.

Among patients without previous CNS disease, brain metastases developed at 24 months in 14.4% (95% CI, 6.1-26.1) of patients in the ALK group who received other TKI’s compared with 48.9% (95% CI ...

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient ...